The Low-Carb Diet for Disease Treatment
Rethinking Chronic Disease: The Case for Carbohydrate Restriction
What if the solution to our most common chronic diseases has been in front of us all along—but we’ve been told to ignore it?
In Nutrition in Crisis, Richard David Feinman argues that the rise of obesity, diabetes, and metabolic syndrome is not just a health crisis—it’s a crisis of science. At the heart of his case is one radical but deeply logical idea: carbohydrate restriction should be the default treatment for metabolic disorders.
Carbs, Insulin, and the Real Cause of Disease
Feinman doesn’t present low-carb eating as a trend or short-term fix. Instead, he frames it as a metabolic correction—a way of realigning how we eat with how our bodies are designed to function. For him, conditions like type 2 diabetes and obesity aren’t just lifestyle diseases. They're diseases of carbohydrate intolerance.
The science is clear: when we consume large amounts of carbs—especially refined ones—our bodies respond by producing insulin. But in many people, especially those with insulin resistance, this system gets overwhelmed. Blood sugar rises. Fat storage increases. Energy crashes. Over time, this creates the perfect environment for metabolic dysfunction.
“If diabetes is a disease of carbohydrate intolerance, why are diabetics told to eat so many carbohydrates?”
For Feinman, this contradiction is nothing short of absurd.
A Broken System
Mainstream medicine has long recommended that diabetics get 45–65% of their calories from carbohydrates. Feinman calls this approach illogical—akin to treating a peanut allergy with peanut butter in moderation.
He highlights a growing body of research showing that when diabetics cut carbs, their blood sugar improves dramatically—often within days. Some can even reduce or stop insulin and medication altogether. Yet this simple, effective intervention is rarely recommended by major health institutions.
Why? Feinman points to a mix of institutional inertia and financial interest. Pharmaceutical companies profit from diabetes treatments. The food industry thrives on processed carbs. And healthcare systems are slow to change course, even when the science is stacked against them.
“We do not need long-term studies to prove the safety of a diet that aligns with human metabolism.”
More Than Just Diabetes
Feinman expands the conversation beyond diabetes. Obesity, he explains, is also misunderstood. We’ve been told it’s about willpower—eat less, move more—but that ignores how hormones like insulin control fat storage. Chronically high insulin from constant carb intake tells the body to store fat and blocks it from burning it.
When you reduce carbs, insulin drops. The body starts burning fat again. It’s not magic—it’s metabolism.
He also dives into cardiovascular health, debunking the long-held belief that fat is the enemy. In fact, low-carb diets improve heart health markers like lowering triglycerides and increasing HDL. Even LDL (often labeled "bad cholesterol") improves in particle size and quality—a more accurate predictor of heart disease than total cholesterol.
“Metabolic syndrome is not just a risk factor for disease—it is a disease itself, and it is caused by excessive carbohydrate consumption.”
Low-Carb Isn’t Unsustainable—We’ve Just Been Doing It Wrong
Critics often argue that low-carb diets are too restrictive to stick with. But Feinman flips this on its head. He says the problem isn’t the diet—it’s the misinformation around it. When done right, low-carb eating is satisfying, varied, and sustainable. Unlike low-fat diets that leave you hungry and depleted, low-carb diets emphasize satiety. You eat less because you need less.
Feinman also touches on emerging research around cancer, pointing out that many tumors rely heavily on glucose. Ketogenic diets, which force the body to run on fat and ketones, may help starve cancer cells. While the science is still early, he argues the potential is too promising to ignore.
The Resistance to Change
One of the most striking parts of this section is Feinman’s criticism of the medical community’s resistance to low-carb interventions. He finds it ironic that critics demand long-term studies for low-carb diets—but offer no such evidence for the high-carb diets they promote. Despite decades of “official” dietary guidelines, chronic disease has only increased.
The reality is, more people are turning to low-carb living—not because they were told to, but because it works. Social media, online communities, and patient-led experimentation have done what official channels haven’t: they’ve made results visible.
“The idea that obesity is simply about eating too much ignores the hormonal regulation of fat storage.”
Feinman’s message is clear: it’s time for a paradigm shift. Low-carb diets are not fringe science. They’re evidence-based, metabolically sound, and life-changing for millions.